Results 281 to 290 of about 496,166 (395)
ERM Inhibition Confers Ferroptosis Resistance through ROS‐Induced NRF2 Signaling
ERM inhibition disrupts ERM‐actin interactions, elevating ROS and triggering KEAP1 degradation, which stabilizes and activates NRF2. Nuclear NRF2 induces cytoprotective genes, notably HMOX1, enhancing redox buffering and suppressing lipid peroxidation to resist erastin‐induced ferroptosis.
Menghao Qiao +19 more
wiley +1 more source
Alternative Splicing (AS) Provides an Alternative Mechanism for Regulating GLIS3 Expression and Activity. [PDF]
Scoville DW +3 more
europepmc +1 more source
Mutant p53 drives oncogenic splicing to promote the progression of ovarian cancer by partnering with the spliceosome factor SNRPD2. Therefore, it is engineered iRGD‐exosomes to co‐deliver siRNAs against both targets. This approach restored tumor‐suppressive mRNA isoforms, effectively enhanced sensitivity to cisplatin, and ultimately blocked tumor ...
Wei Zhao +14 more
wiley +1 more source
The cost of survival: mutation in a barley Strigolactone repressor HvD53A impairs photosynthesis but increases drought tolerance. [PDF]
Korek M +10 more
europepmc +1 more source
A repressor complex governs the integration of flowering signals in Arabidopsis.
Dan Li +9 more
semanticscholar +1 more source
Stroke‐induced lactate accumulation promotes p300‐mediated lactylation of methyl‐CpG binding protein 2 (MeCP2) at lysine 210, which reprograms microglial metabolism toward glycolysis and activates the hexokinase 2 (HK2)/mTOR axis. This cascade promotes proinflammatory responses and impairs neurofunctional outcomes.
Zengyu Zhang +12 more
wiley +1 more source
Prophage Activation: An In Silico Platform for Identifying Prophage Regulatory Elements to Inform Phage Engineering Against Drug-Resistant Bacteria. [PDF]
Musrrat S +6 more
europepmc +1 more source
Discovery of a Novel DNMT1 Inhibitor with Improved Efficacy in Treating β‐Thalassemia
Context of Research: β‐thalassemia affects millions worldwide. DNMT inhibitors are effective HbF‐inducers that benefit patients with β‐thalassemia. Existing DNMT inhibitors are not approved for β‐thalassemia treatment due to dose‐limiting toxicity.What We Find: DMT207 traps DNMT1 into helix‐kinked inactive conformation and enhances its interaction with
Yijie Shen +19 more
wiley +1 more source

